Bispecific antibodies (bsAbs) are antibodies containing two antigen-binding sites and therefore can simultaneously target two different epitopes. As the rising stars in antibody therapeutics, bispecific antibodies have accounted for nearly 20% of the clinical antibody pipeline, with about 160 bsAbs currently in clinical trials.

​With the rapid development of recombinant DNA technology and a deep understanding of antibody engineering, diverse bispecific antibody formats are emerging to pursue optimal biological activity and clinical purposes. Bispecific antibodies have already shown great therapeutic potential in cancer and other diseases, such as diabetes, Alzheimer’s disease and ophthalmological diseases.

Download this whitepaper to learn more about:

• Bispecific antibody drugs on the market
• Design and engineering of bispecific antibodies
• Bispecific antibody expression and production
• Sino Biological’s fast and efficient bsAb expression services